SCHEMBL15832140

SCHEMBL15832140

C=C(CCC)CNC(=C)NCc1ccc(CC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ HPGD P15428 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KMT2A Q03164 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ APAF1 O14727 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ HDAC3 O15379 1/20 0.37
▸ HDAC4 P56524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15832162 0.89 SMN1; SMN2 (0.42) SMN1; SMN2RAB9AHPGDALDH1A1KMT2A
SCHEMBL20778209 0.79 POLB (0.42) POLBSMN1; SMN2RAB9AHPGDALDH1A1
SCHEMBL15832143 0.74 PPID (0.47) POLBHPGDALDH1A1L3MBTL1HDAC3
SCHEMBL15832163 0.74 HPGD (0.41) SMN1; SMN2HPGDALDH1A1KMT2AMEN1
SCHEMBL20924880 0.72 POLB (0.46) POLBSMN1; SMN2RAB9AHPGDALDH1A1
SCHEMBL15832154 0.72 SUCNR1 (0.39) SMN1; SMN2KMT2AMEN1USP2MAPT
SCHEMBL18134836 0.72 CYP3A4 (0.65) HPGDALDH1A1KMT2AL3MBTL1MEN1
SCHEMBL24135396 0.71 CHRM2 (0.44) POLBSMN1; SMN2HPGDALDH1A1KMT2A
SCHEMBL15832164 0.70 PRMT6 (0.45) SMN1; SMN2ALDH1A1GAA
SCHEMBL26749658 0.69 HPGD (0.76) POLBHPGDALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof FKBP3, FKBP4, FKBP5 POLB 4231/4885SMN1; SMN2 2177/4885RAB9A 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback